U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07419841) titled 'A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-10726' on Feb. 12.
Brief Summary: This is a Phase 1, open-label, FIH study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Gastroesophageal Cancer (GC)
Hepatocellular Carcinoma (HCC)
Endometrial Cancer
Renal Cell Carcinoma (RCC)
Intervention:
DRUG: CTX-10726
Intravenous (IV) infusion (0.3-10.0mg/kg) every two weeks.
Recruitment Status: NOT...